AptarGroup, Inc.
ATR
Rangering i aksjer
#2444
AptarGroup, Inc. specializes in developing and manufacturing solutions for... AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma division offers critical components for the pharmaceutical industry, including pumps for nasal allergy remedies, metered dose inhaler valves vital for managing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), elastomeric primary packaging for injectables, and sophisticated active material science innovations. The Beauty + Home segment primarily supplies the personal care and home care sectors with essential products such as pumps, various closures, aerosol valves, accompanying accessories, and sealing mechanisms. It also furnishes the beauty market with pumps and decorative elements. For the food and beverage industries, its Food + Beverage segment delivers a variety of dispensing and non-dispensing closures, specialized elastomeric flow control components, spray pumps, and aerosol valves. AptarGroup markets its offerings globally, utilizing its internal sales team, complemented by independent representatives and distributors across Asia, Europe, Latin America, and North America. The company is engaged in a strategic partnership with PureCycle Technologies LLC to pioneer the integration of ultra-pure recycled polypropylene into advanced dispensing applications. Additionally, it collaborates with Sonmol on the development of a digital platform providing therapies and services, with a particular focus on respiratory and other health conditions. Established in 1992, AptarGroup, Inc. maintains its corporate headquarters in Crystal Lake, Illinois.
Aksjekurs
$125.90
Sist synkronisert: 2026-10-20
Markedsverdi
$8.00B
Endring (1 dag)
0.93%
Endring (1 år)
-3.58%
Land
US
Handel AptarGroup, Inc. (ATR)
Kategori
Healthcare
P/E-forhold for AptarGroup, Inc. (ATR)
P/E-forhold per October 2026 TTM: 21.48
Ifølge AptarGroup, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 21.48. Ved slutten av 2024 hadde selskapet en P/E på 27.82.
P/E-forholdshistorikk for AptarGroup, Inc. fra 2000 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 21.48 | 5.23% |
| 2025 | 20.41 | -26.64% |
| 2024 | 27.82 | -2.42% |
| 2023 | 28.51 | -5.15% |
| 2022 | 30.06 | -8.77% |
| 2021 | 32.95 | -20.03% |
| 2020 | 41.20 | 35.75% |
| 2019 | 30.35 | 0.63% |
| 2018 | 30.16 | 23.19% |
| 2017 | 24.48 | 9.11% |
| 2016 | 22.44 | -1.63% |
| 2015 | 22.81 | 0.60% |
| 2014 | 22.67 | -12.99% |
| 2013 | 26.06 | 33.74% |
| 2012 | 19.48 | 3.07% |
| 2011 | 18.90 | 2.36% |
| 2010 | 18.47 | -4.81% |
| 2009 | 19.40 | 24.53% |
| 2008 | 15.58 | -21.52% |
| 2007 | 19.85 | -0.82% |
| 2006 | 20.01 | 8.89% |
| 2005 | 18.38 | -10.15% |
| 2004 | 20.46 | 15.92% |
| 2003 | 17.65 | 5.07% |
| 2002 | 16.80 | -21.39% |
| 2001 | 21.37 | 30.90% |
| 2000 | 16.32 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 47.48 | 121.10% |
US
|
|
| 27.43 | 27.70% |
FR
|
|
| - | - |
JP
|
|
| 56.89 | 164.91% |
US
|
|
| - | - |
CH
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.